Cargando…

Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer

Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory r...

Descripción completa

Detalles Bibliográficos
Autores principales: McKelvey, Kelly J., Hudson, Amanda L., Prasanna Kumar, Ramyashree, Eade, Thomas, Clarke, Stephen J., Wheeler, Helen R., Diakos, Connie I., Howell, Viive M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971197/
https://www.ncbi.nlm.nih.gov/pubmed/32010614
http://dx.doi.org/10.3389/fonc.2019.01504
_version_ 1783489672779923456
author McKelvey, Kelly J.
Hudson, Amanda L.
Prasanna Kumar, Ramyashree
Eade, Thomas
Clarke, Stephen J.
Wheeler, Helen R.
Diakos, Connie I.
Howell, Viive M.
author_facet McKelvey, Kelly J.
Hudson, Amanda L.
Prasanna Kumar, Ramyashree
Eade, Thomas
Clarke, Stephen J.
Wheeler, Helen R.
Diakos, Connie I.
Howell, Viive M.
author_sort McKelvey, Kelly J.
collection PubMed
description Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory response. We used a murine model to evaluate sub-acute tissue damage and the systemic immune response in C57Bl/6 mice when administered systemic anti-programmed cell death protein 1 (αPD-1) immunotherapy alone or in combination with stereotactic fractionated 10 gray/5 X-ray radiation to normal brain, lung or colon tissue. The model indicated that combinatorial αPD-1 immunotherapy and radiation may alter normal colon cell proliferation and cerebral blood vasculature, and induce systemic thrombocytopenia, lymphopenia, immune suppression, and altered immune repertoire (including interleukin-1β). Therein our data supports close monitoring of hematological and immune-related adverse events in patients receiving combination therapy.
format Online
Article
Text
id pubmed-6971197
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69711972020-02-01 Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer McKelvey, Kelly J. Hudson, Amanda L. Prasanna Kumar, Ramyashree Eade, Thomas Clarke, Stephen J. Wheeler, Helen R. Diakos, Connie I. Howell, Viive M. Front Oncol Oncology Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory response. We used a murine model to evaluate sub-acute tissue damage and the systemic immune response in C57Bl/6 mice when administered systemic anti-programmed cell death protein 1 (αPD-1) immunotherapy alone or in combination with stereotactic fractionated 10 gray/5 X-ray radiation to normal brain, lung or colon tissue. The model indicated that combinatorial αPD-1 immunotherapy and radiation may alter normal colon cell proliferation and cerebral blood vasculature, and induce systemic thrombocytopenia, lymphopenia, immune suppression, and altered immune repertoire (including interleukin-1β). Therein our data supports close monitoring of hematological and immune-related adverse events in patients receiving combination therapy. Frontiers Media S.A. 2020-01-14 /pmc/articles/PMC6971197/ /pubmed/32010614 http://dx.doi.org/10.3389/fonc.2019.01504 Text en Copyright © 2020 McKelvey, Hudson, Prasanna Kumar, Eade, Clarke, Wheeler, Diakos and Howell. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
McKelvey, Kelly J.
Hudson, Amanda L.
Prasanna Kumar, Ramyashree
Eade, Thomas
Clarke, Stephen J.
Wheeler, Helen R.
Diakos, Connie I.
Howell, Viive M.
Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
title Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
title_full Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
title_fullStr Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
title_full_unstemmed Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
title_short Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
title_sort sub-acute toxicity in non-cancerous tissue and immune-related adverse events of a novel combination therapy for cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971197/
https://www.ncbi.nlm.nih.gov/pubmed/32010614
http://dx.doi.org/10.3389/fonc.2019.01504
work_keys_str_mv AT mckelveykellyj subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer
AT hudsonamandal subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer
AT prasannakumarramyashree subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer
AT eadethomas subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer
AT clarkestephenj subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer
AT wheelerhelenr subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer
AT diakosconniei subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer
AT howellviivem subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer